
ICAD Valuation
ICAD Inc
- Overview
- Forecast
- Valuation
- Earnings
ICAD Relative Valuation
ICAD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ICAD is overvalued; if below, it's undervalued.
Historical Valuation
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
3.29
P/B
Median3y
1.64
Median5y
3.68
-2.66
FCF Yield
Median3y
-15.95
Median5y
-11.53
Competitors Valuation Multiple
The average P/S ratio for ICAD's competitors is 12.40, providing a benchmark for relative valuation. ICAD Inc Corp (ICAD) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of -1.61%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch

CELU
Celularity Inc
2.960
USD
-6.33%

CLST
Catalyst Bancorp Inc
12.380
USD
+0.24%

CGBS
Crown LNG Holdings Ltd
0
USD
-64.69%

LSB
LakeShore Biopharma Co Ltd
1.150
USD
-12.21%

FBIO
Fortress Biotech Inc
1.970
USD
+1.55%

BEST
BEST Inc
0
USD
-0.72%

OPI
Office Properties Income Trust
0.277
USD
-13.95%

NVNI
Nvni Group Ltd
0.420
USD
+1.20%

PVL
Permianville Royalty Trust
1.770
USD
-4.32%

XLO
Xilio Therapeutics Inc
0.697
USD
+1.01%
FAQ

Is ICAD Inc (ICAD) currently overvalued or undervalued?
ICAD Inc (ICAD) is now in the Fair zone, suggesting that its current forward PS ratio of NaN is considered Fairly compared with the five-year average of -19.61. The fair price of ICAD Inc (ICAD) is between to according to relative valuation methord.

What is ICAD Inc (ICAD) fair value?

How does ICAD's valuation metrics compare to the industry average?

What is the current P/B ratio for ICAD Inc (ICAD) as of Jul 26 2025?

What is the current FCF Yield for ICAD Inc (ICAD) as of Jul 26 2025?

What is the current Forward P/E ratio for ICAD Inc (ICAD) as of Jul 26 2025?
